Previous Close | 8.97 |
Open | 8.94 |
Bid | 3.64 x 1300 |
Ask | 9.06 x 800 |
Day's Range | 8.83 - 9.12 |
52 Week Range | 7.37 - 14.61 |
Volume | |
Avg. Volume | 376,622 |
Market Cap | 771.321M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 129.29 |
EPS (TTM) | 0.07 |
Earnings Date | Nov 23, 2023 - Nov 28, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.17 |
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enfusion fair value estimate is US$12.93 Enfusion's US$9.11...
NEW YORK & LONDON & HONG KONG, September 18, 2023--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, announced today that on September 15, 2023, it entered into a new $100 million revolving credit facility. The lenders under the credit facility are primarily a syndicate of Enfusion’s relationship banks, including Bank of America, N.A. The credit facility matures on September 15, 2028 and includes an accord
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...